Zeposia (ozanimod) is an oral sphingosine 1-phosphate receptor modulator indicated in adults for relapsing forms of multiple sclerosis and for moderately to severely active ulcerative colitis. It has a titration-based initiation regimen and ongoing post-approval safety monitoring requirements in labeling. U.S. initial approval was in 2020.
Bristol Myers Squibb said 2025 revenue was flat as a 17% increase in growth-portfolio sales offset a 15% decline in legacy drugs. The company expects legacy sales to fall another 12-16% in 2026, with newer products such as Opdivo, Reblozyl and Breyanzi supporting results.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04885894 |
An Examination of Cognitive Fatigue Using Functional Neuroimaging |
RECRUITING |
